Is Innova Captab overvalued or undervalued?

As of 7 March 2025, the valuation grade for Innova Captab has moved from attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 39.37, an EV to EBITDA of 28.57, and a ROE of 13.37%.
Innova Captab's valuation compares to peers such as Sun Pharmaceutical Industries, which is considered expensive with a PE of 35.25, and Cipla Ltd., which is attractive with a PE of 22.99. Despite the recent stock performance showing a 1-year return of 78.8% compared to the Sensex's 7.53%, the current valuation suggests that the stock is fairly valued within its industry context.